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Renal Transplantation Under Cyclophosphamide 
By Thomas E. Starzl, Charles W. Putnam, Charles G. Halgrimson, 
Carl G. Groth, Arthur S. Booth, Jr., and Israel Penn 
BEGINNING 15 mo ago, at the Univer-
sity of Colorado, the alkylating agent, 
cyclophosphamide (Cytoxan), has been 
given an extensive clinical trial in the treat-
ment of whole organ recipients both early 
and late after transplantation. This com-
munication will deal only with those cases 
of renal homotransplantation in which 
cyclophosphamide was used from the out-
set. The late substitution of cyclophospha-
mide for azathioprine has been thoroughly 
described elsewhere. l 
THERAPEUTIC PROTOCOLS 
Cyclophosphamide was given as part of 
a triple drug program that also included 
prednisone and horse ALG. When related 
donors were available, all three agents were 
started several days in advance of opera-
tion (Fig. 1) but for cadaveric cases (Fig. 
2) treatment was started on the day of 
operation. The ALG was confined to the 
first 2-4 mo postoperatively. Prednisone 
was adjusted as needed to control rejection 
(Fig. 1-3). The donor-recipient combina-
tions were not selected on the basis of a 
good HL-A match, and in most instances 
this kind of typing information was not 
even taken into consideration. 
The precise details of treatment during 
the early postoperative period have been 
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published l but it would be good to review 
some significant points. First, the cyclo-
phosphamide was used in almost exactly 
the same way as has been customary with 
azathioprine, designing doses on a day-to-
day basis according to the white counts, 
and with a conscious effort to avoid leuko-
penia. Second, the correct doses on a mil-
ligram per kilogram body weight basis 
were somewhat smaller than would have 
been anticipated had azathioprine rather 
than cyclophosphamide been used. Third, 
attention was paid to the possibility of 
specific toxicity of cyclophosphamide, in-
cluding alopecia, anorexia, and hemorrhagic 
cystitis. At the doses used, alopecia was 
the only complication noted frequently, at 
about a 4% incidence. 
Finally, a change was, as a rule, eventu-
ally made from cyclophosphamide to main-
tenance therapy with azathioprine (Fig. 3). 
At the earliest, this transition was at about 
1 mo posttransplantation and at the latest 
after more than 1 yr. Lately, the switch 
has been carried out arbitrarily after 2 mo 
or before this time if doses of cyclophos-
phamide of at least 0.5 mg/kg have not 
been tolerated without producing leuko-
penia. The rationale for the successive use 
of these two cytotoxic agents lies in the 
dissimilarity of their properties (Fig. 4). 
Cyclophosphamide is an alkylating agent 
said to exert its effect at the premitotic 
(or G2) phase of the cell cycle of immuno-
cytes. In contrast, azathioprine is a purine 
analog that is an inhibitor of DNA syn-
thesis. The objective has been to eliminate 
more effectively the clone of sensitized and 
replicating cells responding to the homo-
graft antigens. The consecutive use of drugs 
in order to achieve "longitudinal" syner-
gism in contrast to the "horizontal" syner-
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Fig. 1. The first 60 days after the transplantation of a kidney from a mother to her 14-yr 
old daughter. The rejection crisis after 1 wk was the most severe observed in the intra-
familial cyclophosphamide series, with the exception of two hyperacute rejections. How-
ever, it was reversed easily and completely. Note that leukopenia was never produced by 
the daily doses of cyclophosphamide that were usually between 0.5 to 1 mg/kg/day. 
Arrow, 625 mg methyl prednisolone intravenously. (By permission of Surg. Gynec. Obstet. 
133:981, 1971. 
gism of simultaneously administered agents 
has become common in cancer chemo-
therapy. 
RESULTS 
Follow-ups of 3-15 mo are now avail-
able. Thirty-nine recipients of related kid-
neys (Table 1) have survived at the rate 
of 90%; kidney survival has been 32 of 
39 (82%). All the living patients now have 
adequate function of their consanguineous 
transplants. 
In recipients of nonrelated kidneys, sur-
vival is 28 of 36 (78%). These 36 patients 
were given 40 kidneys (Table 2) and the 
kidney survival is 73%. It is necessary in 
evaluating these results to appreciate that 
17 of the recipients were entered into the 
series by virtue of their retransplantation 
for the second to fifth times. Kidney sur-
vival was only 10 of 17 (59%) in these 
notoriously bad risk patients with their 
high incidence of presensitization and other 
complications (Table 2). Moreover, six of 
the deaths were in this group. In contrast, 
there was a 10% patient mortality (two 
deaths in recipients undergoing cadaveric 
transplantation for the first time) and a 
CYCLOPHOSPHAMIDE 
Fig. 2. The uncomplicated 
early course of a 20-yr-old re-
cipient of a cadaveric kidney. 
Therapy with cyclophospha-
mide, prednisone, and ALG 
was instituted on the day of 
operation. (By permission of 
Lancet 2:70, 1971). 
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Fig. 3. The first 2 mo posttransplantation of a 14-yr-old recipient of a paternal homo-
graft. Her initial immunosuppressive therapy was with cyclophosphamide, prednisone, and 
horse ALG. The daily doses of cyclophosphamide were always greater than 1.3 mg/kg/ day 
and were given for the first 33 days postoperatively. The switch to azathioprine was then 
made because of a progressive decline in the white blood cell count. The recipient has 
never had a rejection episode and her renal funotion continues to be normal 5 mo 
posttransplantation. 
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present kidney survival of 19 of 23 (83%). 
SUMMARY 
In these studies, cyclophosphamide has 
been shown to be a good enough immuno-
suppressive agent to replace azathioprine 
during the early postoperative period and 
Table 1. Cyclophosphamide: Related Cases' 
Recipients 
Kidneys 
Follow-ups of 3-15 Mo 
Ori'linal 
No. 
39 
39 
Remaining 
No. 
35 
32 
Per 
Cent 
90 
82 
*22 Siblings, 14 parents, 1 aunt, 1 cousin, and 
1 grandmother. 
Fig. 4. The different sites of 
action during the cell cycle of 
the cytotoxic drugs, azathio-
prnie, and cyclophosphamide. 
Rapidly replicating lymphoid 
cells are presumably prefer-
entially susceptible to destruc-
tion by either agent. 
Table 2. Cyclophosphamide: 40 Cadaveric 
Kidneys in 36 Recipients 
Follow-ups of 3-15 Months 
Primary grafts* 
Repeat graftst 
Total 
*2 Deaths 
t6 Deaths 
No. 
23 
17 
40 
Functioning 
19 (83%) 
10 (59%) 
29 (73%) 
for as long as 1 yr with satisfactory results. 
Eventually, cyclophosphamide was replaced 
by azathioprine in most cases. The conse-
cutive use of these chemically and pharma-
cologically dissimilar drugs may have 
advantages in terms of longitudinal syner-
gism. 
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